Molecular Therapy-Oncolytics

Papers
(The TQCC of Molecular Therapy-Oncolytics is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Ferroptosis gene signature in cholangiocarcinoma83
Spatiotemporal analysis of induced neural stem cell therapy to overcome advanced glioblastoma recurrence56
Targeting carcinoembryonic antigen-expressing tumors using a novel transcriptional and translational dual-regulated oncolytic herpes simplex virus type 155
Metabolic remodeling in tumor-associated macrophages contributing to antitumor activity of cryptotanshinone by regulating TRAF6-ASK1 axis48
esRAGE-expressing oHSV enhances anti-tumor efficacy by inhibition of endothelial cell activation44
Reinvigoration of innate and adaptive immunity via therapeutic cellular vaccine for patients with AML40
Efficacy of cancer-specific anti-podoplanin CAR-T cells and oncolytic herpes virus G47Δ combination therapy against glioblastoma37
A novel anti-B7-H3 chimeric antigen receptor from a single-chain antibody library for immunotherapy of solid cancers37
Oncolytic herpes simplex virus armed with a bacterial GBP1 degrader improves antitumor activity36
Cancer stem/progenitor signatures refine the classification of clear cell renal cell carcinoma with stratified prognosis and decreased immunotherapy efficacy36
CAFs/tumor cells co-targeting DNA vaccine in combination with low-dose gemcitabine for the treatment of Panc02 murine pancreatic cancer35
PROTACs in gastrointestinal cancers35
Replication-incompetent influenza A viruses armed with IFN-γ effectively mediate immune modulation and tumor destruction in mice harboring lung cancer34
Durable remission related to CAR-T persistence in R/R B-ALL and long-term persistence potential of prime CAR-T31
Oncolytic virotherapy with chimeric VSV-NDV synergistically supports RIG-I-dependent checkpoint inhibitor immunotherapy30
In vivo DNA-launched bispecific T cell engager targeting IL-13Rα2 controls tumor growth in an animal model of glioblastoma multiforme30
Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia29
The role and application of vesicles in triple-negative breast cancer: Opportunities and challenges28
Pan-cancer analysis reveals distinct clinical, genomic, and immunological features of the LILRB immune checkpoint family in acute myeloid leukemia27
A library of cancer testis specific T cell receptors for T cell receptor gene therapy27
Radiovirotherapy at twenty26
Adding recombinant AAVs to the cancer therapeutics mix26
Pre-treatment with systemic agents for advanced NSCLC elicits changes in the phenotype of autologous T cell therapy products25
Interleukin-6-controlled, mesenchymal stem cell-based sodium/iodide symporter gene therapy improves survival of glioblastoma-bearing mice24
Bacterial cancer therapy using the attenuated fowl-adapted Salmonella enterica serovar Gallinarum24
ScRNA-seq and bulk RNA-seq reveal the characteristics of ferroptosis and establish a risk signature in cholangiocarcinoma24
Oncolytic adenovirus for treatment of malignant ascites24
Seneca Valley virus replicons are packaged in trans and have the capacity to overcome the limitations of viral transgene expression23
DNA-damaging cancer cells to improve virotherapy22
Vaccinia virus and peptide-receptor radiotherapy synergize to improve treatment of peritoneal carcinomatosis22
Thank you to our 2023 reviewers22
Mechanisms of drug resistance in breast cancer liver metastases: Dilemmas and opportunities22
The quest for effective immunotherapies against malignant peripheral nerve sheath tumors: Is there hope?22
Efficacy of coxsackievirus A21 against drug-resistant neoplastic B cells21
Non-coding RNAs and glioma: Focus on cancer stem cells21
An epitope encoded by uORF of RNF10 elicits a therapeutic anti-tumor immune response21
Enhancing the effectiveness of γδ T cells by mRNA transfection of chimeric antigen receptors or bispecific T cell engagers21
Sodium iodide symporter-targeted gene therapy in glioblastoma20
A cross-reactive pH-dependent EGFR antibody with improved tumor selectivity and penetration obtained by structure-guided engineering20
A new strategy for treating colorectal cancer: Regulating the influence of intestinal flora and oncolytic virus on interferon20
Optimized NGFR-derived hinges for rapid and efficient enrichment and detection of CAR T cells in vitro and in vivo20
Multivalent in vivo delivery of DNA-encoded bispecific T cell engagers effectively controls heterogeneous GBM tumors and mitigates immune escape20
0.72763705253601